Emerging drugs to treat obsessive-compulsive disorder

Expert Opinion on Emerging Drugs

Volumn 19, Issue 1, 2014, Pages 67-77

  Pallanti, Stefano ^b   Grassi, Giacomo ^a   Cantisani, Andrea ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anxiety; Medication; Obsessive compulsive disorder; OCD; Treatment

Indexed keywords

GLUTAMIC ACID; MEMANTINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ADDICTION; AMINO ACID DEFICIENCY; AMYGDALOID NUCLEUS; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; COGNITIVE BEHAVIORAL STRESS MANAGEMENT; COGNITIVE THERAPY; COMPETITIVE BEHAVIOR; DISEASE CLASSIFICATION; EARLY DIAGNOSIS; EARLY INTERVENTION; ENVIRONMENTAL EXPOSURE; NEUROMODULATION; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PREFRONTAL CORTEX; PRIMARY HEALTH CARE; REVIEW; TREATMENT INDICATION; TREATMENT RESPONSE;

ANIMALS; HUMANS; OBSESSIVE-COMPULSIVE DISORDER;

EID: 84896734203     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2014.875157     Document Type: Review

References (99)

1. Ruscio AM, Stein DJ, Chiu WT, Kessler RC. The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry 2010;15:53-63
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th edition. American Psychiatric Publishing; Arlington, VA; 2013
3. Insel T, Cuthbert B, Garvey M, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry 2010;167:748-51
4. Figee M, Vink M, de Geus F, et al. Dysfunctional reward circuitry in obsessive-compulsive disorder. Biol Psychiatry 2011;69:867-74
5. Vriend C, de Wit SJ, Remijnse PL, et al. Switch the itch: a naturalistic follow-up study on the neural correlates of cognitive flexibility in obsessivecompulsive disorder. Psychiatry Res 2013;213:31-8
6. de Wit SJ, Alonso P, Schweren L, et al. Multicenter voxel-based morphometry mega-analysis of structural brain scans in obsessive-compulsive disorder. Am J Psychiatry 2013. [Epub ahead of print]
7. van den Heuvel OA, Remijnse PL, Mataix-Cols D, et al. The major symptom dimensions of obsessivecompulsive disorder are mediated by partially distinct neural systems. Brain 2009;132:853-68
8. Grassi G, Pallanti S. Obsessive-compulsive disorder clinical staging: from endophenotype to behavioral addiction. J Behav Addict 2013;2:1-50
9. Kim MJ, Loucks RA, Palmer AL, et al. The structural and functional connectivity of the amygdala: from normal emotion to pathological anxiety. Behav Brain Res 2011;223:403-10
10. Chamberlain SR, Menzies L, Hampshire A, et al. Orbitofrontal dysfunction in patients with obsessivecompulsive disorder and their unaffected relatives. Science 2008;321:421-2 . A landmark study reporting cortical dysfunction to be related with reversal learning in OCD patients and their relatives, suggesting a new candidate endophenotype of the disorder.
11. Chamberlain SR, Blackwell AD, Fineberg NA, et al. The neuropsychology of obsessive compulsive disorder: the importance of failures in cognitive and behavioural inhibition as candidate endophenotypic markers. Neurosci Biobehav Rev 2005;29:399-419
12. Whiteside SP, Port JD, Abramowitz JS. A meta-analysis of functional neuroimaging in obsessive-compulsive disorder. Psychiatry Res 2004;132:69-79
13. Busatto GF, Zamignani DR, Buchpiguel CA, et al. A voxel-based investigation of regional cerebral blood flow abnormalities in obsessivecompulsive disorder using single photon emission computed tomography (SPECT). Psychiatry Res 2000;99:15-27
14. Scarone S, Colombo C, Livian S, et al. Increased right caudate nucleus size in obsessive-compulsive disorder: detection with magnetic resonance imaging. Psychiatry Res 1992;45:115-21
15. Robinson D, Wu H, Munne RA, et al. Reduced caudate nucleus volume in obsessive-compulsive disorder. Arch Gen Psychiatry 1995;52:393-8
16. Szeszko PR, Robinson D, Alvir JM, et al. Orbital frontal and amygdala volume reductions in obsessive-compulsive disorder. Arch Gen Psychiatry 1999;56:913-19
17. Rosenberg DR, Keshavan MS. A.E. Bennett Research Award. Toward a neurodevelopmental model of obsessivecompulsive disorder. Biol Psychiatry 1998;43:623-40
18. Baxter LR Jr, Phelps ME, Mazziotta JC, et al. Local cerebral glucose metabolic rates in obsessive-compulsive disorder. A comparison with rates in unipolar depression and in normal controls. Arch Gen Psychiatry 1987;44:211-18
19. Tobler PN, Christopoulos GI, O'Doherty JP, et al. Risk-dependent reward value signal in human prefrontal cortex. Proc Natl Acad Sci USA 2009;106:7185-90
20. Solomon RL, Kamin LJ, Wynne LC. Traumatic avoidance learning: the outcomes of several extinction procedures with dogs. J Abnorm Psychol 1953;48:291-302
21. Meyer V. Modification of expectations in cases with obsessional rituals. Behav Res Ther 1966;4:273-80
22. Fineberg NA, Potenza MN, Chamberlain SR, et al. Probing compulsive and impulsive behaviors, from animal models to endophenotypes: a narrative review. Neuropsychopharmacology 2010;35:591-604
23. Yadin E, Friedman E, Bridger WH. Spontaneous alternation behavior: an animal model for obsessivecompulsive disorder? Pharmacol Biochem Behav 1991;40:311-15
24. Szechtman H, Sulis W, Eilam D. Quinpirole induces compulsive checking behavior in rats: a potential animal model of obsessive-compulsive disorder (OCD). Behav Neurosci 1998;112:1475-85
25. Shanahan NA, Holick Pierz KA, et al. Chronic reductions in serotonin transporter function prevent 5-HT1B-induced behavioral effects in mice. Biol Psychiatry 2009;65:401-8
26. Shanahan NA, Velez LP, Masten VL, Dulawa SC. Essential role for orbitofrontal serotonin 1B receptors in obsessive-compulsive disorder-like behavior and serotonin reuptake inhibitor response in mice. Biol Psychiatry 2011;70:1039-48
27. Fineberg NA, Chamberlain SR, Hollander E, et al. Translational approaches to obsessive-compulsive disorder: from animal models to clinical treatment. Br J Pharmacol 2011;164:1044-61
28. Hollander E, Wong C. Psychosocial function and economic costs of obsessivecompulsive disorder. CNS Spectr 1998;3:48-58
29. Eisen JL, Sibrava NJ, Boisseau CL, et al. Five-year course of obsessive-compulsive disorder: predictors of remission and relapse. J Clin Psychiatry 2013;74:233-9
30. Nicholson TR, Ferdinando S, Krishnaiah RB, et al. Prevalence of antibasal ganglia antibodies in adult obsessive-compulsive disorder: crosssectional study. Br J Psychiatry 2012;200:381-6
31. Swedo SE, Leckman JF, Rose NR. From research subgroup to clinical syndrome: modifying the PANDAS criteria to describe PANS (Pediatric Acute-onset Neuropsychiatric Syndrome). Pediatr Ther 2012;2:113
32. Labad J, Menchon JM, Alonso P, et al. Gender differences in obsessivecompulsive symptom dimensions. Depress Anxiety 2008;25:832-8
33. Scott J, Leboyer M, Hickie I, et al. Clinical staging in psychiatry: a crosscutting model of diagnosis with heuristic and practical value. Br J Psychiatry 2013;202:243-5 . A relevant paper suggesting the usefulness of a clinical staging model for the assessment of psychiatric disorders.
34. Fineberg NA, Reghunandanan S, Brown A, Pampaloni I. Pharmocotherapy of obsessive-compulsive disorder: evidence-based treatment and beyond. Austr NZ J of Psychiatry 2012;47:121-41
35. Soomro GM, Altman D, Rajagopal S, et al. Selective serotonin reuptake inhibitors (SSRIs) versus placebo for obsessive-compulsive disorder (OCD). Cochrane Database Syst Rev 2008;CD001765
36. Ackerman DL, Greenland S. Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder. J Clin Psychopharmacol 2002;22:309-17
37. Bloch MH, McGuire J, Landeros-Weisenberger A, et al. Meta-analysis of the dose-response relationship of SSRI in obsessivecompulsive disorder. Mol Psychiatry 2010;15:850-5
38. Marazziti D, Baroni S, Faravelli L, et al. Plasma clomipramine levels in adult patients with obsessive-compulsive disorder. Int Clin Psychopharmacol 2012;27:55-60
39. Marazziti D, Baroni S, Giannaccini G, et al. Plasma fluvoxamine levels and OCD symptoms/response in adult patients. Hum Psychopharmacol 2012;27:397-402
40. Denys D, van Megen HJ, van der Wee N, Westenberg HG. A double-blind switch study of paroxetine and venlafaxine in obsessivecompulsive disorder. J Clin Psychiatry 2004;65:37-43
41. Dell'Osso B, Nestadt G, Allen A, Hollander E. Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: a critical review. J Clin Psychiatry 2006;67:600-10
42. Pallanti S, Quercioli L. Treatment-refractory obsessivecompulsive disorder: methodological issues, operational definitions and therapeutic lines. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:400-12
43. Koran LM, Hanna GL, Hollander E, et al. Practice guidelines for the treatment of patients with obsessivecompulsive disorder. Am J Psychiatry 2007;164:5-53
44. Koran LM, Pallanti S, Paiva RS, Quercioli L. Pulse loading versus gradual dosing of intravenous clomipramine in obsessive-compulsive disorder. Eur Neuropsychopharmacol 1998;8:121-6
45. Koran LM, Aboujaude E, Ward H, et al. Pulse-loaded intravenous clomipramine in treatment-resistant obsessivecompulsive disorder. J Clin Psychopharmacol 2006;26:79-83
46. Bogetto F, Albert U, Maina G. Sertraline treatment of obsessive-compulsive disorder: efficacy and tolerability of a rapid titration regimen. Eur Neuropsychopharmacol 2002;12:181-6
47. Whittal ML, Thordarson DS, McLean PD. Treatment ofobsessive-compulsive disorder: cognitive behavior therapy vs. exposure and response prevention. Behav Res Ther 2005;43:1559-76
48. Rufer M, Fricke S, Moritz S, et al. Symptom dimensions in obsessive-compulsive disorder: prediction of cognitive-behavior therapy outcome. Acta Psychiatr Scand 2006;113:440-6
49. Ponniah K, Magiati I, Hollon SD. An update on the efficacy of psychological treatments for obsessive-compulsive disorder in adults. J Obsessive Compuls Relat Disord 2013;2(2):207-18
50. Andersson E, Enander J, Andren P, et al. Internet-based cognitive behaviour therapy for obsessive-compulsive disorder: a randomized controlled trial. Psychol Med 2012;42:2193-203
51. Pallanti S, Hollander E, Bienstock C, et al. Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol 2002;5:181-91
52. Goodman W, Price L, Rasmussen S, et al. The Yale-Brown Obsessive- Compulsive Scale (Y-BOCS), part I: development, use, and reliability. Arch Gen Psychiatry 1989;46:1006-11
53. Goodman W, Price L, Rasmussen S, et al. The Yale-Brown Obsessive- Compulsive Scale (Y-BOCS), part II: validity. Arch Gen Psychiatry 1989;46:1012-16
54. Erzegovesi S, Cavallini M, Cavedini P, et al. Clinical predictors of drug response in obsessive-compulsive disorder. J Clin Psychopharmacol 2001;21:488-92
55. Bloch MH, Landeros-Weisenberger A, Kelmendi B, et al. A systematic review: antipsychotic augmentation with treatment refractory obsessive compulsive disorder. Mol Psychiatry 2006;11:622-32
56. Abudy A, Juven-Wetzler A, Zohar J. Pharmacological management of treatment-resistant obsessive-compulsive disorder. CNS Drugs 2011;25:585-96
57. Pallanti S, Bernardi S, Antonini S, et al. Ondansetron augmentation in treatmentresistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study. CNS Drugs 2009;23:1047-55
58. Soltani F, Sayyah M, Feizy F, et al. A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder. Hum Psychopharmacol 2010;25:509-13
59. Pallanti S, Bernardi S, Antonini S, Singh N, Hollander E. Ondansetron augmentation in patients with Obsessive- Compulsive Disorder who are inadequate responders to serotonin reuptake inhibitors: improvement with treatment and worsening following discontinuation. Eur Neuropsychopharmacol 2013; In press
60. Amiaz R, Fostick L, Gershon A, Zohar J. Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study. Eur Neuropsychopharmacol 2008;18(6):455-61
61. Fallon B, Liebowitz M, Campeas R, et al. Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebocontrolled study. Arch Gen Psychiatry 1998;55:918-24
62. Koran LM, Sallee FR, Pallanti S. Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder. Am J Psychiatry 1997;154:396-401
63. Ross S, Fallon BA, Petkova E, et al. Long-term follow-up study of patients with refractory obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci 2008;20:450-7
64. Pallanti S, Quercioli L, Koran LM. Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial. J Clin Psychiatry 2002;63:796-801
65. Grassi G, Pallanti S. Citalopram pulseloading for severe treatment-resistant OCD: a case series of acute response, one year follow-up and tolerability. J Depress Anxiety 2013;In press
66. Berlim MT, Neufeld NH, Van den Eynde F. Repetitive transcranial magnetic stimulation (rTMS) for obsessive-compulsive disorder (OCD): an exploratory meta-analysis of randomized and sham-controlled trials. J Psychiatr Res 2013;47:999-1006
67. Fontenelle LF, Mendlowicz MV, Versiani M. The descriptive epidemiology of obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:327-37
68. Hankin CS, Koran L, Sheehan DV, et al. Patients with obsessive-compulsive disorder vs depression have comparable health care costs: a retrospective claims analysis of Florida Medicaid enrollees. Ann Clin Psychiatry 2011;23:285-96
69. Murray CJL, Lopez AD. The global burden of disease. Harvard University Press; Cambridge, MA; 1996
70. Koran LM. Quality of life in obsessivecompulsive disorder. Psychiatr Clin North Am 2000;23:509-17
71. Rosenberg DR, MacMaster FP, Keshavan MS, et al. Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry 2000;39:1096-103
72. Rosenberg DR, MacMillan SN, Moore GJ. Brain anatomy and chemistry may predict treatment response in pediatric obsessive-compulsive disorder. Int J Neuropsychopharmacol 2001;4:179-90
73. Bolton J, Moore GJ, MacMillan S, et al. Case study: caudate glutamatergic changes with paroxetine persist after medication discontinuation in pediatric OCD. J Am Acad Child Adolesc Psychiatry 2001;40:903-6
74. Carlsson ML. On the role of cortical glutamate in obsessive-compulsive disorder and attention-deficit hyperactivity disorder, two phenomenologically antithetical conditions. Acta Psychiatr Scand 2000;102:401-13
75. Moore GJ, MacMaster FP, Stewart C, et al. Case study: caudate glutamatergic changes with paroxetine therapy for pediatric obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 1998;37:663-7
76. Chakrabarty K, Bhattacharyya S, Christopher R, et al. Glutamatergic dysfunction in OCD. Neuropsychopharmacology 2005;30:1735-40
77. Bhattacharyya S, Khanna S, Chakrabarty K, et al. Anti-brain antibodies and altered excitatoryneurotrasmitters in obsessivecompulsive disorder. Neuropsychopharmacology 2009;34:2489-96
78. El Mansari M, Blier P. Mechanism of action of current and potential pharmacotherapies of obsessivecompulsive disorder. Prog Neuropsychopharmacol 2006;30:362-73
79. Arnold PD, Rosenberg DR, Mundo E, et al. Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study. Psychopharmacology (Berl) 2004;174:530-8
80. Arnold PD, Sicard T, Burroughs E, et al. Glutamate transporter gene SLC1A1 associated with obsessivecompulsive disorder. Arch Gen Psychiatry 2006;63:769-76
81. Dickel DE, Veenstra-VanderWeele J, Cox NJ, et al. Association testing of the positional and functional candidate gene SLC1A1/EAAC1 in early-onset obsessivecompulsive disorder. Arch Gen Psychiatry 2006;63:778-85
82. Welch JM, Lu J, Rodriguiz RM, et al. Cortico-striatal synaptic defects and OCD-like behavior in SAPAP3 mutant mice. Nature 2007;448:894-900 . An important research supporting the involvement and the importance of cortico-striatal circuitry in OCD-like behaviors.
83. Hezel DM, Beattie K, Stewart SE. Memantine as augmenting agent for severe pediatric OCD. Am J Psychiatry 2009;166:237
84. Poyurovsky M, Weizman R, Weizman A, et al. Memantine for treatment-resistant OCD. Am J Psychiatry 2005;162:2191-2
85. Pasquini M, Biondi M. Memantine augmentation for refractory obsessivecompulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:1173-5
86. Feusner JD, Kerwin L, Saxena S, Bystritsky A. Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open label trial. Psychopharmacol Bull 2009;42:81-93
87. Aboujaoude E, Barry JJ, Gamel N. Memantine augmentation in treatmentresistant obsessive-compulsive disorder. J Clin Psychopharmacol 2009;29:51-5
88. Stewart SE, Jenike EA, Hezel DM, et al. A single-blinded case-control study of memantine in severe obsessivecompulsive disorder. J Clin Psychopharmacol 2010;30:34-9
89. Ghaleiha A, Entezari N, Modabbernia A, et al. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebocontrolled study. J Psychiatr Res 2013;47:175-80
90. Haghighi M, Jahangard L, Mohammad-Beigi H, et al. In a doubleblind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD). Psychopharmacology (Berl) 2013;228:633-40
91. Coric V, Taskiran S, Pittenger C, et al. Riluzole augmentation in treatmentresistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry 2005;58:424-8
92. Grant P, Lougee L, Hirschtritt M, Swedo SE. An open-label trial of riluzole, a glutamate antagonist, in children with treatment resistant obsessive-compulsive disorder. J Clin Adolescent Psychopharmacol 2007;17:761-7
93. Afshar H, Roohafza H, Mohammad-Beigi H, et al. N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebocontrolled trial. J Clin Psychopharmacol 2012;32:797-803
94. Rodriguez CI, Kegeles LS, Levinson A, et al. Randomized controlled crossover trial of ketamine in obsessive compulsive disorder: proof-of-concept. Neuropsychopharmacology 2013. [Epub ahead of print]
95. Available from: http://clinicaltrials.gov/ct2/show/record/NCT01674361
96. Available from: http://clinicaltrials.gov/show/NCT00216294
97. Leckman JF, Rauch SL, Mataix-Cols D. Symptom dimensions in obsessivecompulsive disorder: implications for the DSM-V. CNS Spectr 2007;12:376-87
98. Nestadt G, Di CZ, Riddle MA, et al. Obsessive-compulsive disorder: subclassification based on comorbidity. Psychol Med 2009;39:1491-501
99. Pinto A, Steinglass JE, Greene AL, et al. Capacity to delay reward differentiates obsessive-compulsive disorder and obsessive-compulsive personality disorder. Biol Psychiatry 2013; In press